OXB

We're thrilled to welcome David Backer back to OXB as our new Durham Site Head! With more than 30 years of experience in biotechnology and life sciences, Dave brings extensive expertise in cell and gene therapy, biologics manufacturing and business operations. Having previously worked with OXB, he combines deep industry knowledge with a strong understanding of our business and clients. We look forward to Dave leading our Durham site as we continue to deliver excellence for our clients and the patients they serve. Please join us in welcoming Dave back to OXB. #OXB #Leadership #CellAndGeneTherapy #CDMO #ViralVectors 

We are delighted to welcome Eric Schmidhäuser to OXB as our new Chief Operating Officer. Eric brings more than 30 years of international leadership experience across various industries, including pharmaceutical manufacturing, CDMO operations and supply chain management. His extensive experience in the CDMO sector and proven track record of leading complex, multi-site organisations will be invaluable to us as we continue to execute our multi-site, multi-vector strategy and support our partners in bringing life-changing therapies to patients. Please join us in welcoming Eric to OXB. #OXB #Leadership #CellAndGeneTherapy #CDMO #ViralVectors

𝐐𝐮𝐚𝐥𝐢𝐭𝐲 𝐢𝐬 𝐚𝐛𝐨𝐮𝐭 𝐦𝐨𝐫𝐞 𝐭𝐡𝐚𝐧 𝐜𝐨𝐦𝐩𝐥𝐢𝐚𝐧𝐜𝐞. 𝐈𝐭'𝐬 𝐚𝐛𝐨𝐮𝐭 𝐛𝐮𝐢𝐥𝐝𝐢𝐧𝐠 𝐜𝐨𝐧𝐟𝐢𝐝𝐞𝐧𝐜𝐞 𝐚𝐭 𝐞𝐯𝐞𝐫𝐲 𝐬𝐭𝐚𝐠𝐞 𝐨𝐟 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭.   In this edition of 5 Questions with..., Dr. Melanie C J Kearney, SVP, Global Head of Quality at OXB, explores why Quality should be embedded from the very beginning of a cell and gene therapy programme. Read the interview to learn how a proactive quality mindset can reduce risk, accelerate progress and support successful commercialisation.   https://lnkd.in/eBB27cCe #OXB #Quality #CDMO #ViralVectors #CellAndGeneTherapy

How can we accelerate lentiviral vector process development while improving confidence in scale-up? In collaboration with atSpiro, our new white paper explores how ShakeReactors™ can help bridge the gap between early-stage experimentation and manufacturing-scale performance. The study demonstrates how ShakeReactors™ can deliver reproducible process insights, support optimisation and help reduce scale-up risk by capturing key large scale bioreactor behaviours. Download the white paper to learn how this approach can support more efficient viral vector process development: https://lnkd.in/gkJVwfqk #CellAndGeneTherapy #AdvancedTherapies #ViralVectors #CDMO #OXB

𝐈𝐬 𝐲𝐨𝐮𝐫 𝐂𝐃𝐌𝐎 𝐡𝐞𝐥𝐩𝐢𝐧𝐠 𝐲𝐨𝐮 𝐛𝐮𝐢𝐥𝐝 𝐚 𝐬𝐮𝐬𝐭𝐚𝐢𝐧𝐚𝐛𝐥𝐞 𝐚𝐧𝐝 𝐫𝐞𝐬𝐢𝐥𝐢𝐞𝐧𝐭 𝐬𝐮𝐩𝐩𝐥𝐲 𝐜𝐡𝐚𝐢𝐧? With increasing geopolitical uncertainty, evolving regulatory expectations and growing demand for manufacturing flexibility, choosing a CDMO is about choosing a partner that is invested in your long-term ambitions and success. 👉 Swipe through to explore the five questions we believe every biotech should be asking their CDMO. #CDMO #ViralVectors #AdvancedTherapies #CellAndGeneTherapy

𝗬𝗼𝘂𝗿 𝗲𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 𝗰𝗼𝘂𝗹𝗱 𝗵𝗲𝗹𝗽 𝘀𝗵𝗮𝗽𝗲 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗰𝗲𝗹𝗹 𝗮𝗻𝗱 𝗴𝗲𝗻𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝘆. We're looking for talented people to join our teams across Production, Quality and Support teams at OXB. Every role plays an important part in delivering the quality and reliability our partners rely on to advance their programmes. Working alongside colleagues in the UK, US and France, you'll develop your career while contributing to the manufacture of viral vectors that support the development of advanced therapies. 𝐈𝐧𝐭𝐞𝐫𝐞𝐬𝐭𝐞𝐝 𝐢𝐧 𝐣𝐨𝐢𝐧𝐢𝐧𝐠 𝐎𝐗𝐁? 🔗 Explore our current opportunities and discover where your expertise could make an impact: https://careers.oxb.com/ #CellAndGeneTherapy #AdvancedTherapies #ViralVectors #CDMO #OXB 

We're delighted to have been selected by Plowshare Therapies LLC to provide process development and GMP manufacturing services for their AAV programme. This programme will be supported from our FDA-approved facility in Durham, North Carolina, highlighting the strength of our expanding US manufacturing network and continued momentum across our AAV business. Read our press release here: https://lnkd.in/ehiwv2g9 #CDMO #ViralVectors #AAV #GMP #CellAndGeneTherapy

Supply chain resilience has become a strategic priority for advanced therapy developers. From geopolitical uncertainty to commercial scale-up, today's manufacturing decisions can have long-term implications for programme success. What's your biggest concern when it comes to securing your supply chain? Vote below and tell us why in the comments. We'll share the questions we believe you should be asking your CDMO for building a more resilient supply chain next week. #CDMO #ViralVectors #CellAndGeneTherapy #AdvancedTherapies

Manufacturing is not a simple operational step. It is fundamental to delivering safe, consistent, high-quality treatments to patients.   At our Capital Markets Event, a fireside chat with Dr. Sebastien Ribault, Chief Business Officer at OXB, and Dr. Arun Das, MD, Chief Business Officer at Cabaletta Bio, reinforced a critical reality in cell & gene therapy - choosing the right CDMO partner is essential to success.   As Arun noted, “the process is the product”, and shared why Cabaletta has chosen to partner with OXB since 2019:   🔹Track record and proven expertise in viral vector manufacturing 🔹Global capabilities and a commitment to innovation 🔹A true partnership mindset, built on trust, collaboration, and cultural fit   To watch the full fireside chat, click the link in the comments.   #CapitalMarketsEvent #CDMO #ViralVectors #CellAndGeneTherapy

We're live at #BIO2026 at 𝗯𝗼𝗼𝘁𝗵 𝟱𝟮𝟭𝟲! Come and meet the OXB team, learn more about our support for cell and gene therapy programmes, and experience a virtual tour of our global sites through our 𝗩𝗥 𝗲𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲. If you're attending BIO, stop by and say hello. #CellAndGeneTherapy #AdvancedTherapies #ViralVectors #CDMO #OXB